ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Lysosomal Storage Disorders Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-4Q13596
Home | Market Reports | Health| Health Conditions| Genetic Disorders
Global Lysosomal Storage Disorders Market Research Report 2023
BUY CHAPTERS

Global Lysosomal Storage Disorders Market Research Report 2025

Code: QYRE-Auto-4Q13596
Report
May 2025
Pages:85
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astellas Pharma
Astrazeneca plc
Actelion Ltd
Eli Lilly and Company
Merck
Novo Nordisk
Amicus Therapeutics
Pfizer Inc
Sanofi
BioMarin Pharmaceutical Inc
Raptor Pharmaceuticals
Protalix BioTherapeutics, Inc.

Lysosomal Storage Disorders Market Size

The global market for Lysosomal Storage Disorders was valued at US$ 1493 million in the year 2024 and is projected to reach a revised size of US$ 2572 million by 2031, growing at a CAGR of 8.2% during the forecast period.

Lysosomal Storage Disorders Market

Lysosomal Storage Disorders Market

Lysosomal storage diseases or disorders (LSDs) are rare genetic conditions that cause a buildup of toxic materials in your body"s cells. People with LSDs lack certain enzymes or a substance that helps the enzyme work (enzyme activator or modifier).
The global lysosomal storage disorders (LSD) market refers to the market for therapeutic treatments, diagnostic tools, and supportive care for various lysosomal storage disorders. Lysosomal storage disorders are a group of rare genetic disorders characterized by the accumulation of specific substances within the lysosomes of cells. These disorders result from deficiencies of enzymes or transporters responsible for breaking down these substances.
Lysosomal storage disorders can affect various organs and systems in the body, leading to a wide range of symptoms and complications. Some common lysosomal storage disorders include Gaucher disease, Fabry disease, Pompe disease, Niemann-Pick disease, and mucopolysaccharidoses.
The market for lysosomal storage disorders is driven by several factors. Firstly, increased awareness and advancements in diagnostic techniques have led to improved detection and diagnosis of these disorders. This has resulted in a growing patient population and a higher demand for therapeutic interventions.
Secondly, advancements in treatment options, including enzyme replacement therapies, substrate reduction therapies, gene therapies, and chaperone therapies, have significantly improved patient outcomes. These innovative therapies aim to restore or replace the deficient enzymes, reduce the accumulation of substrates, or correct the underlying genetic defect.
Thirdly, supportive care and management play a crucial role in the overall treatment of lysosomal storage disorders. This includes symptomatic relief, physical therapy, nutrition management, genetic counseling, and psychological support. The market for supportive care products and services is also an important aspect of the overall lysosomal storage disorders market.
The market for lysosomal storage disorders is segmented based on the type of disorder, treatment modality, end-user, and geography. The types of disorders may include Gaucher disease, Fabry disease, Pompe disease, Niemann-Pick disease, mucopolysaccharidoses, and others. Treatment modalities may include enzyme replacement therapies, substrate reduction therapies, gene therapies, chaperone therapies, and others. End-users of these therapies and products include hospitals, specialty clinics, research centers, and homecare settings.
Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe hold a significant market share due to the presence of established healthcare infrastructure, high awareness, and supportive reimbursement policies. The Asia Pacific region is expected to witness rapid market growth due to improving healthcare infrastructure, increasing awareness, and growing investments in research and development.
Key players in the global lysosomal storage disorders market include pharmaceutical companies, biotechnology companies, and research organizations. These companies focus on research and development activities, clinical trials, and collaborations to bring innovative therapies and diagnostic tools to the market. They also work towards improving access to these therapies, especially in regions with limited healthcare infrastructure or resources.
In summary, the global lysosomal storage disorders market is driven by factors such as increased awareness, advancements in diagnostic techniques, and innovative treatment options. The market encompasses therapeutic interventions, diagnostic tools, and supportive care products and services. With ongoing research and development efforts, the market is expected to grow as more effective and targeted therapies become available, improving the quality of life for patients with lysosomal storage disorders.The global lysosomal storage disorders (LSD) market refers to the market for therapeutic treatments, diagnostic tools, and supportive care for various lysosomal storage disorders. Lysosomal storage disorders are a group of rare genetic disorders characterized by the accumulation of specific substances within the lysosomes of cells. These disorders result from deficiencies of enzymes or transporters responsible for breaking down these substances.
Lysosomal storage disorders can affect various organs and systems in the body, leading to a wide range of symptoms and complications. Some common lysosomal storage disorders include Gaucher disease, Fabry disease, Pompe disease, Niemann-Pick disease, and mucopolysaccharidoses.
The market for lysosomal storage disorders is driven by several factors. Firstly, increased awareness and advancements in diagnostic techniques have led to improved detection and diagnosis of these disorders. This has resulted in a growing patient population and a higher demand for therapeutic interventions.
Secondly, advancements in treatment options, including enzyme replacement therapies, substrate reduction therapies, gene therapies, and chaperone therapies, have significantly improved patient outcomes. These innovative therapies aim to restore or replace the deficient enzymes, reduce the accumulation of substrates, or correct the underlying genetic defect.
Thirdly, supportive care and management play a crucial role in the overall treatment of lysosomal storage disorders. This includes symptomatic relief, physical therapy, nutrition management, genetic counseling, and psychological support. The market for supportive care products and services is also an important aspect of the overall lysosomal storage disorders market.
The market for lysosomal storage disorders is segmented based on the type of disorder, treatment modality, end-user, and geography. The types of disorders may include Gaucher disease, Fabry disease, Pompe disease, Niemann-Pick disease, mucopolysaccharidoses, and others. Treatment modalities may include enzyme replacement therapies, substrate reduction therapies, gene therapies, chaperone therapies, and others. End-users of these therapies and products include hospitals, specialty clinics, research centers, and homecare settings.
Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe hold a significant market share due to the presence of established healthcare infrastructure, high awareness, and supportive reimbursement policies. The Asia Pacific region is expected to witness rapid market growth due to improving healthcare infrastructure, increasing awareness, and growing investments in research and development.
Key players in the global lysosomal storage disorders market include pharmaceutical companies, biotechnology companies, and research organizations. These companies focus on research and development activities, clinical trials, and collaborations to bring innovative therapies and diagnostic tools to the market. They also work towards improving access to these therapies, especially in regions with limited healthcare infrastructure or resources.
In summary, the global lysosomal storage disorders market is driven by factors such as increased awareness, advancements in diagnostic techniques, and innovative treatment options. The market encompasses therapeutic interventions, diagnostic tools, and supportive care products and services. With ongoing research and development efforts, the market is expected to grow as more effective and targeted therapies become available, improving the quality of life for patients with lysosomal storage disorders.
This report aims to provide a comprehensive presentation of the global market for Lysosomal Storage Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lysosomal Storage Disorders.
The Lysosomal Storage Disorders market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Lysosomal Storage Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lysosomal Storage Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Lysosomal Storage Disorders Market Report

Report Metric Details
Report Name Lysosomal Storage Disorders Market
Accounted market size in year US$ 1493 million
Forecasted market size in 2031 US$ 2572 million
CAGR 8.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Clinics
  • Stem Cell Transplant Centre
  • Research Institutes
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Astellas Pharma, Astrazeneca, Actelion, Eli Lilly and Company, Merck & Co, Novo Nordisk, Amicus Therapeutics, Pfizer, Sanofi, BioMarin Pharmaceutical Inc., Raptor Pharmaceuticals, Protalix Biotherapeutics Inc
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Lysosomal Storage Disorders company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Lysosomal Storage Disorders Market growing?

Ans: The Lysosomal Storage Disorders Market witnessing a CAGR of 8.2% during the forecast period 2025-2031.

What is the Lysosomal Storage Disorders Market size in 2031?

Ans: The Lysosomal Storage Disorders Market size in 2031 will be US$ 2572 million.

Who are the main players in the Lysosomal Storage Disorders Market report?

Ans: The main players in the Lysosomal Storage Disorders Market are Astellas Pharma, Astrazeneca, Actelion, Eli Lilly and Company, Merck & Co, Novo Nordisk, Amicus Therapeutics, Pfizer, Sanofi, BioMarin Pharmaceutical Inc., Raptor Pharmaceuticals, Protalix Biotherapeutics Inc

What are the Application segmentation covered in the Lysosomal Storage Disorders Market report?

Ans: The Applications covered in the Lysosomal Storage Disorders Market report are Hospital, Clinics, Stem Cell Transplant Centre, Research Institutes, Others

What are the Type segmentation covered in the Lysosomal Storage Disorders Market report?

Ans: The Types covered in the Lysosomal Storage Disorders Market report are Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, Chaperone Therapy, Others

Recommended Reports

Lysosomal Disorders

Genetic Syndromes

Neurological Disorders

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lysosomal Storage Disorders Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Enzyme Replacement Therapy
1.2.3 Stem Cell Therapy
1.2.4 Substrate Reduction Therapy
1.2.5 Chaperone Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Lysosomal Storage Disorders Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Stem Cell Transplant Centre
1.3.5 Research Institutes
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lysosomal Storage Disorders Market Perspective (2020-2031)
2.2 Global Lysosomal Storage Disorders Growth Trends by Region
2.2.1 Global Lysosomal Storage Disorders Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Lysosomal Storage Disorders Historic Market Size by Region (2020-2025)
2.2.3 Lysosomal Storage Disorders Forecasted Market Size by Region (2026-2031)
2.3 Lysosomal Storage Disorders Market Dynamics
2.3.1 Lysosomal Storage Disorders Industry Trends
2.3.2 Lysosomal Storage Disorders Market Drivers
2.3.3 Lysosomal Storage Disorders Market Challenges
2.3.4 Lysosomal Storage Disorders Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lysosomal Storage Disorders Players by Revenue
3.1.1 Global Top Lysosomal Storage Disorders Players by Revenue (2020-2025)
3.1.2 Global Lysosomal Storage Disorders Revenue Market Share by Players (2020-2025)
3.2 Global Lysosomal Storage Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Lysosomal Storage Disorders Revenue
3.4 Global Lysosomal Storage Disorders Market Concentration Ratio
3.4.1 Global Lysosomal Storage Disorders Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lysosomal Storage Disorders Revenue in 2024
3.5 Global Key Players of Lysosomal Storage Disorders Head office and Area Served
3.6 Global Key Players of Lysosomal Storage Disorders, Product and Application
3.7 Global Key Players of Lysosomal Storage Disorders, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Lysosomal Storage Disorders Breakdown Data by Type
4.1 Global Lysosomal Storage Disorders Historic Market Size by Type (2020-2025)
4.2 Global Lysosomal Storage Disorders Forecasted Market Size by Type (2026-2031)
5 Lysosomal Storage Disorders Breakdown Data by Application
5.1 Global Lysosomal Storage Disorders Historic Market Size by Application (2020-2025)
5.2 Global Lysosomal Storage Disorders Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Lysosomal Storage Disorders Market Size (2020-2031)
6.2 North America Lysosomal Storage Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Lysosomal Storage Disorders Market Size by Country (2020-2025)
6.4 North America Lysosomal Storage Disorders Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lysosomal Storage Disorders Market Size (2020-2031)
7.2 Europe Lysosomal Storage Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Lysosomal Storage Disorders Market Size by Country (2020-2025)
7.4 Europe Lysosomal Storage Disorders Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lysosomal Storage Disorders Market Size (2020-2031)
8.2 Asia-Pacific Lysosomal Storage Disorders Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Lysosomal Storage Disorders Market Size by Region (2020-2025)
8.4 Asia-Pacific Lysosomal Storage Disorders Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lysosomal Storage Disorders Market Size (2020-2031)
9.2 Latin America Lysosomal Storage Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Lysosomal Storage Disorders Market Size by Country (2020-2025)
9.4 Latin America Lysosomal Storage Disorders Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lysosomal Storage Disorders Market Size (2020-2031)
10.2 Middle East & Africa Lysosomal Storage Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Lysosomal Storage Disorders Market Size by Country (2020-2025)
10.4 Middle East & Africa Lysosomal Storage Disorders Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Pharma
11.1.1 Astellas Pharma Company Details
11.1.2 Astellas Pharma Business Overview
11.1.3 Astellas Pharma Lysosomal Storage Disorders Introduction
11.1.4 Astellas Pharma Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.1.5 Astellas Pharma Recent Development
11.2 Astrazeneca
11.2.1 Astrazeneca Company Details
11.2.2 Astrazeneca Business Overview
11.2.3 Astrazeneca Lysosomal Storage Disorders Introduction
11.2.4 Astrazeneca Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.2.5 Astrazeneca Recent Development
11.3 Actelion
11.3.1 Actelion Company Details
11.3.2 Actelion Business Overview
11.3.3 Actelion Lysosomal Storage Disorders Introduction
11.3.4 Actelion Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.3.5 Actelion Recent Development
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Details
11.4.2 Eli Lilly and Company Business Overview
11.4.3 Eli Lilly and Company Lysosomal Storage Disorders Introduction
11.4.4 Eli Lilly and Company Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.4.5 Eli Lilly and Company Recent Development
11.5 Merck & Co
11.5.1 Merck & Co Company Details
11.5.2 Merck & Co Business Overview
11.5.3 Merck & Co Lysosomal Storage Disorders Introduction
11.5.4 Merck & Co Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.5.5 Merck & Co Recent Development
11.6 Novo Nordisk
11.6.1 Novo Nordisk Company Details
11.6.2 Novo Nordisk Business Overview
11.6.3 Novo Nordisk Lysosomal Storage Disorders Introduction
11.6.4 Novo Nordisk Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.6.5 Novo Nordisk Recent Development
11.7 Amicus Therapeutics
11.7.1 Amicus Therapeutics Company Details
11.7.2 Amicus Therapeutics Business Overview
11.7.3 Amicus Therapeutics Lysosomal Storage Disorders Introduction
11.7.4 Amicus Therapeutics Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.7.5 Amicus Therapeutics Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Lysosomal Storage Disorders Introduction
11.8.4 Pfizer Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.8.5 Pfizer Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Lysosomal Storage Disorders Introduction
11.9.4 Sanofi Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.9.5 Sanofi Recent Development
11.10 BioMarin Pharmaceutical Inc.
11.10.1 BioMarin Pharmaceutical Inc. Company Details
11.10.2 BioMarin Pharmaceutical Inc. Business Overview
11.10.3 BioMarin Pharmaceutical Inc. Lysosomal Storage Disorders Introduction
11.10.4 BioMarin Pharmaceutical Inc. Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.10.5 BioMarin Pharmaceutical Inc. Recent Development
11.11 Raptor Pharmaceuticals
11.11.1 Raptor Pharmaceuticals Company Details
11.11.2 Raptor Pharmaceuticals Business Overview
11.11.3 Raptor Pharmaceuticals Lysosomal Storage Disorders Introduction
11.11.4 Raptor Pharmaceuticals Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.11.5 Raptor Pharmaceuticals Recent Development
11.12 Protalix Biotherapeutics Inc
11.12.1 Protalix Biotherapeutics Inc Company Details
11.12.2 Protalix Biotherapeutics Inc Business Overview
11.12.3 Protalix Biotherapeutics Inc Lysosomal Storage Disorders Introduction
11.12.4 Protalix Biotherapeutics Inc Revenue in Lysosomal Storage Disorders Business (2020-2025)
11.12.5 Protalix Biotherapeutics Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Astellas Pharma
Astrazeneca plc
Actelion Ltd
Eli Lilly and Company
Merck
Novo Nordisk
Amicus Therapeutics
Pfizer Inc
Sanofi
BioMarin Pharmaceutical Inc
Raptor Pharmaceuticals
Protalix BioTherapeutics, Inc.
List of Tables
 Table 1. Global Lysosomal Storage Disorders Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Enzyme Replacement Therapy
 Table 3. Key Players of Stem Cell Therapy
 Table 4. Key Players of Substrate Reduction Therapy
 Table 5. Key Players of Chaperone Therapy
 Table 6. Key Players of Others
 Table 7. Global Lysosomal Storage Disorders Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Lysosomal Storage Disorders Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Lysosomal Storage Disorders Market Size by Region (2020-2025) & (US$ Million)
 Table 10. Global Lysosomal Storage Disorders Market Share by Region (2020-2025)
 Table 11. Global Lysosomal Storage Disorders Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 12. Global Lysosomal Storage Disorders Market Share by Region (2026-2031)
 Table 13. Lysosomal Storage Disorders Market Trends
 Table 14. Lysosomal Storage Disorders Market Drivers
 Table 15. Lysosomal Storage Disorders Market Challenges
 Table 16. Lysosomal Storage Disorders Market Restraints
 Table 17. Global Lysosomal Storage Disorders Revenue by Players (2020-2025) & (US$ Million)
 Table 18. Global Lysosomal Storage Disorders Market Share by Players (2020-2025)
 Table 19. Global Top Lysosomal Storage Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lysosomal Storage Disorders as of 2024)
 Table 20. Ranking of Global Top Lysosomal Storage Disorders Companies by Revenue (US$ Million) in 2024
 Table 21. Global 5 Largest Players Market Share by Lysosomal Storage Disorders Revenue (CR5 and HHI) & (2020-2025)
 Table 22. Global Key Players of Lysosomal Storage Disorders, Headquarters and Area Served
 Table 23. Global Key Players of Lysosomal Storage Disorders, Product and Application
 Table 24. Global Key Players of Lysosomal Storage Disorders, Date of Enter into This Industry
 Table 25. Mergers & Acquisitions, Expansion Plans
 Table 26. Global Lysosomal Storage Disorders Market Size by Type (2020-2025) & (US$ Million)
 Table 27. Global Lysosomal Storage Disorders Revenue Market Share by Type (2020-2025)
 Table 28. Global Lysosomal Storage Disorders Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 29. Global Lysosomal Storage Disorders Revenue Market Share by Type (2026-2031)
 Table 30. Global Lysosomal Storage Disorders Market Size by Application (2020-2025) & (US$ Million)
 Table 31. Global Lysosomal Storage Disorders Revenue Market Share by Application (2020-2025)
 Table 32. Global Lysosomal Storage Disorders Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 33. Global Lysosomal Storage Disorders Revenue Market Share by Application (2026-2031)
 Table 34. North America Lysosomal Storage Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America Lysosomal Storage Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 36. North America Lysosomal Storage Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Europe Lysosomal Storage Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Europe Lysosomal Storage Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 39. Europe Lysosomal Storage Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 40. Asia-Pacific Lysosomal Storage Disorders Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Asia-Pacific Lysosomal Storage Disorders Market Size by Region (2020-2025) & (US$ Million)
 Table 42. Asia-Pacific Lysosomal Storage Disorders Market Size by Region (2026-2031) & (US$ Million)
 Table 43. Latin America Lysosomal Storage Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Latin America Lysosomal Storage Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Latin America Lysosomal Storage Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Middle East & Africa Lysosomal Storage Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 47. Middle East & Africa Lysosomal Storage Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 48. Middle East & Africa Lysosomal Storage Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 49. Astellas Pharma Company Details
 Table 50. Astellas Pharma Business Overview
 Table 51. Astellas Pharma Lysosomal Storage Disorders Product
 Table 52. Astellas Pharma Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 53. Astellas Pharma Recent Development
 Table 54. Astrazeneca Company Details
 Table 55. Astrazeneca Business Overview
 Table 56. Astrazeneca Lysosomal Storage Disorders Product
 Table 57. Astrazeneca Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 58. Astrazeneca Recent Development
 Table 59. Actelion Company Details
 Table 60. Actelion Business Overview
 Table 61. Actelion Lysosomal Storage Disorders Product
 Table 62. Actelion Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 63. Actelion Recent Development
 Table 64. Eli Lilly and Company Company Details
 Table 65. Eli Lilly and Company Business Overview
 Table 66. Eli Lilly and Company Lysosomal Storage Disorders Product
 Table 67. Eli Lilly and Company Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 68. Eli Lilly and Company Recent Development
 Table 69. Merck & Co Company Details
 Table 70. Merck & Co Business Overview
 Table 71. Merck & Co Lysosomal Storage Disorders Product
 Table 72. Merck & Co Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 73. Merck & Co Recent Development
 Table 74. Novo Nordisk Company Details
 Table 75. Novo Nordisk Business Overview
 Table 76. Novo Nordisk Lysosomal Storage Disorders Product
 Table 77. Novo Nordisk Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 78. Novo Nordisk Recent Development
 Table 79. Amicus Therapeutics Company Details
 Table 80. Amicus Therapeutics Business Overview
 Table 81. Amicus Therapeutics Lysosomal Storage Disorders Product
 Table 82. Amicus Therapeutics Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 83. Amicus Therapeutics Recent Development
 Table 84. Pfizer Company Details
 Table 85. Pfizer Business Overview
 Table 86. Pfizer Lysosomal Storage Disorders Product
 Table 87. Pfizer Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 88. Pfizer Recent Development
 Table 89. Sanofi Company Details
 Table 90. Sanofi Business Overview
 Table 91. Sanofi Lysosomal Storage Disorders Product
 Table 92. Sanofi Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 93. Sanofi Recent Development
 Table 94. BioMarin Pharmaceutical Inc. Company Details
 Table 95. BioMarin Pharmaceutical Inc. Business Overview
 Table 96. BioMarin Pharmaceutical Inc. Lysosomal Storage Disorders Product
 Table 97. BioMarin Pharmaceutical Inc. Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 98. BioMarin Pharmaceutical Inc. Recent Development
 Table 99. Raptor Pharmaceuticals Company Details
 Table 100. Raptor Pharmaceuticals Business Overview
 Table 101. Raptor Pharmaceuticals Lysosomal Storage Disorders Product
 Table 102. Raptor Pharmaceuticals Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 103. Raptor Pharmaceuticals Recent Development
 Table 104. Protalix Biotherapeutics Inc Company Details
 Table 105. Protalix Biotherapeutics Inc Business Overview
 Table 106. Protalix Biotherapeutics Inc Lysosomal Storage Disorders Product
 Table 107. Protalix Biotherapeutics Inc Revenue in Lysosomal Storage Disorders Business (2020-2025) & (US$ Million)
 Table 108. Protalix Biotherapeutics Inc Recent Development
 Table 109. Research Programs/Design for This Report
 Table 110. Key Data Information from Secondary Sources
 Table 111. Key Data Information from Primary Sources
 Table 112. Authors List of This Report


List of Figures
 Figure 1. Lysosomal Storage Disorders Picture
 Figure 2. Global Lysosomal Storage Disorders Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Lysosomal Storage Disorders Market Share by Type: 2024 VS 2031
 Figure 4. Enzyme Replacement Therapy Features
 Figure 5. Stem Cell Therapy Features
 Figure 6. Substrate Reduction Therapy Features
 Figure 7. Chaperone Therapy Features
 Figure 8. Others Features
 Figure 9. Global Lysosomal Storage Disorders Market Size by Application (2020-2031) & (US$ Million)
 Figure 10. Global Lysosomal Storage Disorders Market Share by Application: 2024 VS 2031
 Figure 11. Hospital Case Studies
 Figure 12. Clinics Case Studies
 Figure 13. Stem Cell Transplant Centre Case Studies
 Figure 14. Research Institutes Case Studies
 Figure 15. Others Case Studies
 Figure 16. Lysosomal Storage Disorders Report Years Considered
 Figure 17. Global Lysosomal Storage Disorders Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 18. Global Lysosomal Storage Disorders Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 19. Global Lysosomal Storage Disorders Market Share by Region: 2024 VS 2031
 Figure 20. Global Lysosomal Storage Disorders Market Share by Players in 2024
 Figure 21. Global Top Lysosomal Storage Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lysosomal Storage Disorders as of 2024)
 Figure 22. The Top 10 and 5 Players Market Share by Lysosomal Storage Disorders Revenue in 2024
 Figure 23. North America Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. North America Lysosomal Storage Disorders Market Share by Country (2020-2031)
 Figure 25. United States Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Canada Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Europe Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Europe Lysosomal Storage Disorders Market Share by Country (2020-2031)
 Figure 29. Germany Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. France Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. U.K. Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Italy Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Russia Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Nordic Countries Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Asia-Pacific Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Asia-Pacific Lysosomal Storage Disorders Market Share by Region (2020-2031)
 Figure 37. China Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Japan Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. South Korea Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. India Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Australia Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Latin America Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Latin America Lysosomal Storage Disorders Market Share by Country (2020-2031)
 Figure 45. Mexico Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Brazil Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Middle East & Africa Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Middle East & Africa Lysosomal Storage Disorders Market Share by Country (2020-2031)
 Figure 49. Turkey Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. UAE Lysosomal Storage Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 52. Astellas Pharma Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 53. Astrazeneca Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 54. Actelion Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 55. Eli Lilly and Company Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 56. Merck & Co Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 57. Novo Nordisk Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 58. Amicus Therapeutics Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 59. Pfizer Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 60. Sanofi Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 61. BioMarin Pharmaceutical Inc. Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 62. Raptor Pharmaceuticals Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 63. Protalix Biotherapeutics Inc Revenue Growth Rate in Lysosomal Storage Disorders Business (2020-2025)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Lysosomal Storage Diseases Market Research Report 2024
Global Lysosomal Storage Disease Treatment Drugs Market Research Report 2024
Global Sphingolipidoses Treatment Market Research Report 2025
Global Lysosomal Storage Disease Treatment Market Research Report 2024
Global Lysosomal Storage Disorder Drugs Market Research Report 2024
Mucopolysaccharidosis Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Mucopolysaccharidosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Krabbe Disease Treatment Market Research Report 2024
Global Fabry Disease Treatment Market Insights Forecast to 2030
Gaucher Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Gaucher Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Gaucher Disease GD Drugs Market Insights Forecast to 2030
Alpha Mannosidosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Mucopolysaccharidosis MPS Treatment Market Research Report 2024
Lysosomal Acid Lipase Deficiency Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Familial Chylomicronemia Syndrome Therapeutics Market Research Report 2025
Adrenoleukodystrophy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Inherited Metabolic Disorder Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
POEMS Syndrome Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pompe Disease Treatment Market Research Report 2024

RELATED REPORTS

Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24R5886
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Lysosomal Storage Diseases Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34Q5936
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Acute Intermittent Porphyria Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6U7336
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Phenylketonuria Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12R6229
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions